학술논문

Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial
Document Type
Article
Source
In: The Lancet Oncology. (The Lancet Oncology, March 2023, 24(3):213-227)
Subject
Language
English
ISSN
14745488
14702045